T1	Participants 463 626	From December 1997 through February 2003, 244 men with newly diagnosed localized prostate cancer were randomly assigned to cryoablation or EBRT (median dose 68 Gy)
T2	Participants 628 682	All patients received neoadjuvant antiandrogen therapy
T3	Participants 684 832	Patients completed the EORTC QLQ C30 and the Prostate Cancer Index (PCI) before treatment and at 1.5, 3, 6, 12, 18, 24, and 36 months post-treatment
T4	Participants 72 112	patients with localized prostate cancer:
